Literature DB >> 12270119

Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes.

Peter Vanlandschoot1, Annelies Roobrouck, Freya Van Houtte, Geert Leroux-Roels.   

Abstract

Yeast expressed Hepatitis B surface antigen (rHBsAg) binds to monocytes through interaction with the LPS binding protein (LBP) and the LPS receptor CD14. Charged phospholipids of rHBsAg determine the interaction with these proteins. Although attachment of rHBsAg resembles the pro-inflammatory binding of LPS to CD14, rHBsAg does not activate monocytes and even reduces the expression of pro-inflammatory cytokines by LPS-stimulated monocytes. It is reported here that addition of rHBsAg to LPS-stimulated PBMC often results in increased secretion of IL-10, suggesting a similarity between the interaction of monocytes with apoptotic cells and rHBsAg. Using THP-1 cells, it is shown that IL-10 is not necessary to reduce TNFalpha protein levels. Addition of rHBsAg to LPS-stimulated cells reduces TNFalpha mRNA levels, but does not affect phosphorylation of p65 NF-kappaB and p38 MAP kinase. Instead, a reduced phosphorylation of ERK-1/2 and JNK-1/2 MAP kinases is observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270119     DOI: 10.1016/s0006-291x(02)02243-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Old and new adjuvants for hepatitis B vaccines.

Authors:  Geert Leroux-Roels
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

2.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

3.  Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.

Authors:  Marjoleine L Op den Brouw; Rekha S Binda; Mark H van Roosmalen; Ulrike Protzer; Harry L A Janssen; Renate G van der Molen; Andrea M Woltman
Journal:  Immunology       Date:  2008-06-28       Impact factor: 7.397

4.  Study of human B7 homolog 1 expression in patients with hepatitis B virus infection.

Authors:  Wen-Jin Zhang; Hai-Yang Xie; Xin Duan; Yun-Le Wan; Chuan-Hui Peng; Shao-Hua Shi; Rong Su; Zhang-Hui Zheng; Le-Lin Pan; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

5.  Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.

Authors:  Moses T Bility; Liang Cheng; Zheng Zhang; Yan Luan; Feng Li; Liqun Chi; Liguo Zhang; Zhengkun Tu; Yanhang Gao; Yangxin Fu; Junqi Niu; Fusheng Wang; Lishan Su
Journal:  PLoS Pathog       Date:  2014-03-20       Impact factor: 6.823

Review 6.  Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.

Authors:  Yanqin Du; Jun Wu; Jia Liu; Xin Zheng; Dongliang Yang; Mengji Lu
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

7.  Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection.

Authors:  Yasuteru Kondo; Masashi Ninomiya; Eiji Kakazu; Osamu Kimura; Tooru Shimosegawa
Journal:  ISRN Gastroenterol       Date:  2013-01-16

8.  Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Authors:  Branwen J Hennig; Katherine Fielding; John Broxholme; Mathurin Diatta; Maimuna Mendy; Catrin Moore; Andrew J Pollard; Pura Rayco-Solon; Giorgio Sirugo; Marianne A van der Sande; Pauline Waight; Hilton C Whittle; Syed M Zaman; Adrian V Hill; Andrew J Hall
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

9.  Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease.

Authors:  Arjan Boltjes; Zwier M Groothuismink; Gertine W van Oord; Harry L A Janssen; Andrea M Woltman; André Boonstra
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.